Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) reached a new 52-week low during trading on Friday . The stock traded as low as $10.92 and last traded at $11.32, with a volume of 341203 shares traded. The stock had previously closed at $11.98.
Maze Therapeutics Stock Up 6.0 %
About Maze Therapeutics
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
- Five stocks we like better than Maze Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Business Services Stocks Investing
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
